Press release: Paving the way for machine learning with medical data
Read moreData science specialist CASUS and the PIONEER research consortium ally in the fight against prostate cancer The Centre for Advanced Systems Understanding (CASUS) at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has joined PIONEER, a € 12.8m euro project funded by the...
Big Data 4 Better Outcomes: Recommendations for the European Health Data Space
Read moreCoordinated by PIONEER the five Big Data 4 Better Outcomes (BD4BO) projects of the Innovative Medicines Initiative have come together in light of their experience to make recommendations to inform EU decision makers in order to respond to the...
Odysseus Data Services, Inc. joins PIONEER study-a-thon effort as sponsoring partner
Read moreOdysseus will join forces with PIONEER, EHDEN and OHDSI to progress the ongoing PIONEER Study-a-thon. The study-a-thon is investigating the natural history and outcomes of prostate cancer patients managed with watchful waiting. A conservative management option for prostate cancer...
News Flash – New PIONEER data partner!
Read morePIONEER welcomes new data partner the Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol) from Catalonia, Spain. IDIAPJGol will participate in the PIONEER consortium providing results from its large Information System for Research in...
PIONEER presents at the OHDSI Community Call
Read moreThe May 18 OHDSI Community Call featured a presentation from six representatives (Kees van Bochove, Giorgio Gandaglia, Asieh Golozar, Bertrand de Meulder, Ariel Achtman, and Robert Snijder) from the PIONEER Prostate Cancer Study-A-Thon. They provided a full report on the five-day...
PIONEER News Flash – Three new data providers join the consortium
Read morePIONEER The European Network of Excellence for Big Data in Prostate Cancer welcomes three new external data providers to the consortium as Data Sharing Agreements signed with the Netherlands Cancer Registry (NCR), the Estonian Biobank (EBB) and the Lithuanian...
Contact us here
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
